Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Andy Dang, PharmD Candidate
Andy Dang is a PharmD candidate at the University of Houston College of Pharmacy in Texas.
Articles
Finerenone and the Future of Diabetes-Related Kidney Care
Andy Dang, PharmD Candidate;Natalie Rosario, PharmD, MPH, BCACP;Elisabeth M. Wang, PharmD, BCCP;Shantera Davis, PharmD, BCPS;K’bria Whaley, PharmD Candidate;Joshua Wollen, PharmD
July 15th 2025Finerenone emerges as a promising treatment for patients with diabetes and chronic kidney disease, significantly reducing cardiovascular and renal risks.
Read More
Latest Updated Articles
Published: June 12th 2025 | Updated: June 16th 2025
Study: How Individual Carbohydrate Responses Reveal Metabolic Health and Potential Biomarkers
Published: June 10th 2025 | Updated: June 12th 2025
Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members
Published: June 2nd 2025 | Updated: June 11th 2025
NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
Published: June 3rd 2025 | Updated: June 11th 2025
ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape
Published: May 30th 2025 | Updated: June 5th 2025
Emerging Data: Impacts of ROCKstar and AGAVE-201
Published: April 18th 2025 | Updated: April 21st 2025
Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders
